Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shuhui You"'
Autor:
Shihui Hu, Yannan Zhao, Yizhao Xie, Shuhui You, Xichun Hu, Jian Zhang, Leiping Wang, Jun Cao, Chengcheng Gong, Biyun Wang
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
ObjectiveWith the approval of trastuzumab deruxtecan for the treatment of unresectable/metastatic HER2-low breast cancer, human epidermal growth factor receptor 2 (HER2)-low has emerged as a clinically actionable biomarker. There is an urgent need fo
Externí odkaz:
https://doaj.org/article/3d5bed5376144891810c7abd19b8248f
Autor:
Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu, Xichun Hu, Shaoli Song, Biyun wang, Zhongyi Yang
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic
Externí odkaz:
https://doaj.org/article/e5a09c0e73834eac9ad0bdbae032ea73
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Pyrotinib, an irreversible pan-human epidermal growth (HER) inhibitor, has proven its antitumor efficacy as a second-line treatment for HER2-positive metastatic breast cancer (HER2+ MBC) when combined with capecitabine. However, real-worl
Externí odkaz:
https://doaj.org/article/4dea617c19ac4795a7ea69e24afcf9ae
Autor:
Shuhui You, Yizhao Xie, Mengjing Ji, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shihui Hu, Yumeng Li, Zhongyi Yang, Biyun Wang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT) technique provides a convenient method to evaluate the overall estrogen receptor (ER) expression in metastatic breast cancer (MBC) patients. There a
Externí odkaz:
https://doaj.org/article/780dbc0555ed448086747b2f4b2c8e82
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectivePyrotinib and pertuzumab are effective treatment options for HER2-positive metastatic breast cancer (HER2+ MBC). Our study was to directly compare the efficacy and safety of pyrotinib plus trastuzumab (PyroH) and pertuzumab plus trastuzumab
Externí odkaz:
https://doaj.org/article/8498e7ce732f4014bdb8a05c40ff20e6
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
ObjectiveDespite the promising efficacy of the novel antibody-drug conjugate trastuzumab deruxtecan in treating Hormone Receptor (HoR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-low metastatic breast cancer (MBC), its categorization as
Externí odkaz:
https://doaj.org/article/ee6bef37d6d94cbbaf517c1f0c616794
Autor:
Yizhao Xie, Xinyue Du, Yannan Zhao, Chengcheng Gong, Shihui Hu, Shuhui You, Shaoli Song, Xichun Hu, Zhongyi Yang, Biyun Wang
Publikováno v:
Cancers; Volume 14; Issue 14; Pages: 3531
Background: The heterogeneity of estrogen receptor (ER) expression has long been a challenge for the diagnosis and treatment strategy of metastatic breast cancer (MBC). A novel convenient method of ER detection using 18F-fluoroestradiol positron emis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15213fc672c384165c8b5341c77d3456